ReviewCurrent pain and headache reports2026
Neuroimmune Phenotyping as the Next Frontier in Chronic Pain Medicine for Musculoskeletal Back Pain.
Review in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic low back pain encompasses heterogeneous mechanical, neuropathic, nociplastic, and myofascial presentations that may reflect distinct neuroimmune mechanisms. We synthesized evidence linking these phenotypes to measurable biological features and clinically relevant treatment strategies.
methodsWe conducted a structured literature search of MEDLINE, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials for studies published from January 2005 through January 2025. Systematic reviews, randomized controlled trials, and mechanistic studies addressing neuroinflammation, glial activation, central sensitization, biomarkers, or imaging were organized according to four clinically relevant pain phenotypes and translational readiness.
resultsNeuroimmune findings differed across axial mechanical, radicular neuropathic, nociplastic, and myofascial pain. Imaging of the 18-kDa translocator protein demonstrated phenotype-associated neuroinflammatory patterns, whereas shear wave elastography provided an objective measure of myofascial trigger-point stiffness. Combining inflammatory biomarkers with psychosocial characteristics improved chronic pain prediction, with reported areas under the receiver operating characteristic curve ranging from 0.69 to 0.92. Evidence also supported phenotype-aligned approaches including targeted rehabilitation, ultrasound-guided dry needling, dorsal root ganglion stimulation, and spinal cord stimulation. However, biomarker validation, imaging standardization, and clinical availability varied substantially.
conclusionNeuroimmune phenotyping provides a framework for connecting pain mechanisms with diagnostic and therapeutic strategies in chronic low back pain. Shear wave elastography and selected inflammatory measures appear closest to clinical implementation, while advanced neuroimaging and multi-omic approaches remain investigational. Phenotype-enriched prospective trials are needed before routine precision-guided management can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.